CAMBRIDGE, UK 30 March 2021 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the appointment of Michael Daniels, PhD, as Head of Product Management. In this role, Dr Daniels will be focused on the development and introduction of Evonetix’s first product, a DNA desktop writer. He will work closely with the prospective customers and users of the Company’s products as well as the team’s engineers and research scientists.
Dr Daniels brings with him over 15 years’ experience of…
Turnover at leading pharmaceutical and biotech product development consultancy Boyds has surged by a record-breaking 25 percent as demand for its specialist services continues to grow.
The company, which was established 16 years ago by Professor Alan Boyd and supports the development of medicines for patient benefit, has already added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles to enhance its expertise, service demand for its services, and expand the business.
Boyds has partnered with UK…
AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells.Being animal-free, these enzymes are very safe and offer reduced regulatory hurdles for use in clinical applications. They are manufactured under GMP guidelines using a plant-based production process that guarantees no risk of cross-contamination with animal-derived materials. These top-quality enzymes can be used on a wide range of cell/tissue types and…
From mobile apps to digital biomarkers, transformative technologies – such as
artificial intelligence, machine learning and virtual reality – are enabling the creation of unique and novel digital health innovations, ultimately changing our definition of what a medical device is. By crossing the line from tracking, to diagnosis and treatment using tools like AI symptom checkers, a product is no longer classified as a wellness consumer product, but instead it becomes a medical device. Spanning from sample detection and diagnosis to the treatment of mental health disorders, the opportunities are…
Sioux Falls, South Dakota, United States and Cambridge, UK – 25 March 2021–Sanford Health (‘Sanford’), a leading US-based healthcare delivery system provider and Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples’ lives, today announce a genomics partnership focused on providing answers for patients and families with hard to diagnose rare diseases.
Congenica is recognized as a global leader in the rapid genomic analysis of complex genomic data in rare diseases. Globally, over 300 million people live with a rare disease, of…
PrecisionLife today announces that it has acquired its long-term Danish technology development partner GenoKey ApS, bringing together the leaders in combinatorial analytics and large-scale genomic analysis, and enabling PrecisionLife to continue its expansion as an AI-enabled precision medicine company. Financial details of the paper-based transaction were not disclosed.
PrecisionLife’s platform, which includes technology developed with GenoKey, enables the company to gain unique insights into genes associated with disease, as biomarkers and as targets for drug discovery. PrecisionLife’s…
Cambridge, UK, 23 March 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’…
Cambridge, UK, 17 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a key milestone in the Company’s mission to develop the most complete human ‘body-on-a-chip’ in the…
Manufactured in dedicated clean-rooms with mandated changeovers before new production cycles - AMSBIO introduces new pHelper-Kan plasmid DNA optimized for Adeno-Associated Virus (AAV) manufacturing.Adeno-associated virus is a non-enveloped virus that can be engineered to efficiently deliver DNA sequences of interest into target cells with a low immunogenicity. Because of these unique characteristics, AAV-mediated genome editing has emerged as a highly promising gene delivery method.The robust virus packaging productivity of this pHelper-Kan plasmid has been tested in almost all AAV serotypes…
Glasgow, UK, 17 March 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and Gilde Healthcare. Additional investors in this round include Novartis Venture Fund, and Eli Lilly and Company, joining existing investor BioMotiv and founding investor Advent Life Sciences. The proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to…